2nd Stratified Medicine Conference

Stratified medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology. As a result, this will enable improved diagnostic tests, more precise diagnoses, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient but also the appropriate dosage to reduce adverse effects.

ExL’s 2nd Stratified Medicine Conference will bring together the industry’s leading stratified and personalized medicine experts to provide you with unique take-home examples, case studies and multiple innovative strategies to implement stratified medicine initiatives within your own organizations.

By attending this conference, you will hear industry-specific case studies and examples including:

  • Pathways to partnership in therapeutic-diagnostic development
  • The future of translational research and stratified medicine Innovations in detecting molecular malfunctions impacting cancer research and 
therapy
  • The role of biomarkers and translational science in the discovery organization
  • Pursuing stratified medicine: via predictive biomarkers to enhance clinical decision 
making
  • The regulatory path to approval via stratified medicine Integrating clinical benefits with the economic implications
  • Examining the importance of pharmacokinetic biomarkers in early clinical 
development decision points
  • Stratifying patients for clinical trials based on molecular and clinical data
  • Examining the challenges of companion diagnostics in pharmaceutical development
  • Exploring models for industry / academia collaboration in stratified medicine

Benefit from industry participation from Pfizer, Merck, MedImmune, Johnson & Johnson, Novartis, Selventa, EMD Serono, Daiichi Sankyo, MIT, and many more personalized and stratified medicine innovators and experts.

 

Attend January’s Stratified Medicine Conference and join the industry’s leading stratified and personalized medicine experts to provide you with unique take-home examples, case studies and multiple innovative strategies to implement stratified medicine initiatives within your own organizations. 

This is a MUST ATTEND event for professionals involved in stratified medicine, biomarkers, clinical development and personalized medicine.  Participants will benefit from unique take-home examples, case studies and multiple clinical development strategies to assist in initiating and implementing a stratified medicines program, while shortening clinical phases, reducing costs, increasing approval rate, and time-to-market on your future drug products.

 

Testimonials:

“Great presentations, clear discussions and good Q&A!”
– Director, Takeda

“Excellent discussions on challenges with biomarkers in drug development”
– Sr. Scientist, BD Diagnostics

“Great discussions, good content”
– Sajit Brar, FDA

Who Should Attend

CSOs, Vice Presidents, Heads, Directors, Scientists and Project Leaders of:

  • Biomarker Discovery / Validation / Qualification
  • Clinical Research / Development / Pharmacology / Pathology
  • Translational Medicine / Experimental Medicine / Stratified Medicine
  • Molecular and Cell Biology
  • Bioinformatics
  • Genomics
  • Oncology / Diabetes and Metabolism / CNS / Cardiology / Endocrinology / Respiratory & Inflammation
  • Regulatory Affairs
  • Pharmacokinetics / Pharmacodynamics / Drug Safety Assessment
  • Diagnostics
  • Imaging
  • Regulatory Affairs
  • Proteomics
  • Next Generation Sequencing
  • Epigenetics
  • Strategic Partnering / Business Development